Modern History of Medical Cannabis : From Widespread Use to Prohibitionism and Back Simona Pisanti and Maurizio Bifulco Trends in Pharmacological Sciences, Cell Press, 2017, 38, 3, 195-198. doi: 10.1016/j.tips.2016.12.002. Over the history of pharmacology there are numerous examples of drugs being widely distributed, almost ‘trendy’, prescribed by physicians in a certain period as a sort of panacea, and then neglected, forgotten, or even forbidden as they become considered dangerous in the light of clinical observations. One of these drugs is Cannabis, which was very popular in the 19th century until disappearing from the official Pharmacopoeia at the beginning of the 20th century and [...]
Lire la suiteThe Need for Federal Regulation of Marijuana Marketing John W. Ayers, PhD, Theodore Caputi, Eric C. Leas, PhD,MPH JAMA, June 11, 2019 Volume 321, Number 22 doi:10.1001/jama.2019.4432 A national for-profit marijuana industry is expanding substantially in the United States. Thirty-three states have legalized medical marijuana, 10 of which (where 1 in 4 individuals reside) have also legalized recreational marijuana. Sales of marijuana are projected to increase from $8.5 billion to $75 billion by 2030, rivaling current tobacco sales ($125 billion).1 The initial marijuana marketplace was limited to a few states, but emerging brands have developed sophisticated national marketing campaigns that could potentially have an [...]
Lire la suiteCSSS-N Commissions de la sécurité sociale et de la santé publique Secrétariat CH-3003 Berne www.parlament.ch sgk.csss@parl.admin.ch Vendredi, 03 mai 2019 15h50 Communiqué de presse Essais pilotes avec du cannabis: premier obstacle franchi La Commission de la sécurité sociale et de la santé publique du Conseil national est entrée en matière sur le projet prévoyant la création d’un article relatif aux projets pilotes dans la loi sur les stupéfiants. Elle souhaite permettre la réalisation d’études scientifiques sur la remise contrôlée de cannabis en vue d’une consommation récréative. Par 12 voix contre 9 et 2 abstentions, la Commission de la sécurité sociale et de la santé publique [...]
Lire la suiteUsages d’alcool, de tabac et de cannabis chez les adolescents du secondaire en 2018 Stanislas Spilka, Emmanuelle Godeau (EHESP), Olivier Le Nézet, Virginie Ehlinger (Inserm UMR 1027), Eric Janssen, Alex Brissot, Antoine Philippon, Sandra Chyderiotis Tendances, juin 2018 Observatoire français des drogues et des toxicomanies Observer les premiers usages de substances psychoactives chez les adolescents selon le niveau scolaire [1, 2] permet d’analyser le calendrier de diffusion des consommations pour la mise en oeuvre d’actions de prévention et de politiques de santé publique : quand et où intervenir auprès des élèves, quelles sont les classes « pivots » au cours desquelles les expérimentations s’amorcent ou [...]
Lire la suiteAssociation between medical cannabis laws and opioid overdose mortality has reversed over time Chelsea L. Shover, Corey S. Davis, Sanford C. Gordon, and Keith Humphreys PNAS, mai 2019 www.pnas.org/cgi/doi/10.1073/pnas.1903434116 Abstract Medical cannabis has been touted as a solution to the US opioid overdose crisis since Bachhuber et al. [M. A. Bachhuber, B. Saloner, C. O. Cunningham, C. L. Barry, JAMA Intern. Med. 174, 1668–1673] found that from 1999 to 2010 states with medical cannabis laws experienced slower increases in opioid analgesic overdose mortality. That research received substantial attention in the scientific literature and popular press and served as a talking point for the cannabis industry [...]
Lire la suiteMedical Cannabis No Solution to the Opioid Crisis Batya Swift Yasgur, MA, LSW Medscape Medical News, June 11, 2019 https://www.medscape.com/viewarticle/914256?nlid=130206_2052&src=WNL_mdplsnews_190614_mscpedit_psyc&uac=292598PZ&spon=12&impID=1994987&faf=1 Contrary to previous research and popular assumptions, legalization of, and broader access to, medical cannabis has not reduced opioid overdose death rates. A study at Stanford University in California showed no protective effect of medical cannabis. In fact, states that legalized medical cannabis actually experienced a 22.7% increase in opioid overdose deaths. "There has been an idea touted by people and the cannabis industry and everyone invested in finding solutions to the opioid crisis that passing cannabis laws is one way to do that," lead author [...]
Lire la suiteHas the Legalisation of Medical and Recreational Cannabis Use in the USA Affected the Prevalence of Cannabis Use and Cannabis Use Disorders ? Janni Leung, Chui Ying Vivian Chiu, Daniel Stjepanović & Wayne Hall Current Addiction Reports, 2018, 5, 403–417 https://doi.org/10.1007/s40429-018-0224-9 Published online: 21 September 2018 # Springer Nature Switzerland AG 2018 Abstract Purpose of Review Since California legalised medical use of cannabis in 1996, 29 other US states have done so. Eight US states have legalised the retail sale of cannabis to adults over the age of 21 years since 2012. Critics of these policy changes have suggested that they will increase the prevalence of cannabis [...]
Lire la suiteDebate over recreational cannabis use legalisation in Canada Paul Webster The Lancet, 2018, 391, 725-726 www.thelancet.com February 24, 2018 The Trudeau Government presents this proposed law as a boon for public health and safety, but debate rages over cannabis-harm reduction in youths. Paul Webster reports from Toronto. As Canada prepares to legalise recreational cannabis use next summer, the government faces increasingly tough questions about a widely praised national drug control experiment being closely watched internationally. “We’re approaching it purely from a public health and safety standpoint”, Prime Minister Justin Trudeau explained in a televised gathering in Toronto last autumn. “The questions around revenue and taxation are [...]
Lire la suiteDoes cannabis legalisation change healthcare utilisation? A population-based study using the healthcare cost and utilisation project in Colorado, USA Francesca N Delling, Eric Vittinghoff, Thomas A Dewland, Mark J Pletcher, Jeffrey E Olgin, Gregory Nah, Kirstin Aschbacher, Christina D Fang, Emily S Lee, Shannon M Fan, Dhruv S Kazi, Gregory M Marcus BMJ Open, 2019, 9:e027432 http:// dx.doi. org/ 10. 1136/ bmjopen- 2018-027432). Abstract Objective : To assess the effect of cannabis legalisation on health effects and healthcare utilisation in Colorado (CO), the first state to legalise recreational cannabis, when compared with two control states, New York (NY) and Oklahoma (OK). Design : We used the [...]
Lire la suiteCannabis Where are we and where are we going ? Bilan sur les statuts du cannabis dans le monde Le groupe Edison a publié une revue sur le statut du cannabis dans le monde. Où sommes-nous et où allons-nous? EDISON Healthcare, 30 April 2019 The cannabis sector is relatively broad, spanning FDA-approved drugs toconsumer products. Both markets are still at a fraction of their potential peak sizes due to laws forbidding the use of cannabis and also regulatory hesitance to approve drugs with related active ingredients. Worldwide sales for all regulator-approved cannabinoid therapeutics were only $53m in 2018 while the total legal cannabis market [...]
Lire la suite